Krystal Biotech (KRYS) Competitors $148.17 -1.57 (-1.05%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$150.57 +2.40 (+1.62%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KRYS vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMCShould you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Krystal Biotech vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Krystal Biotech (NASDAQ:KRYS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability. Does the media refer more to KRYS or ITCI? In the previous week, Krystal Biotech had 15 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 16 mentions for Krystal Biotech and 1 mentions for Intra-Cellular Therapies. Krystal Biotech's average media sentiment score of 0.39 beat Intra-Cellular Therapies' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer KRYS or ITCI? Krystal Biotech presently has a consensus price target of $213.75, indicating a potential upside of 44.26%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is KRYS or ITCI more profitable? Krystal Biotech has a net margin of 37.17% compared to Intra-Cellular Therapies' net margin of -14.07%. Krystal Biotech's return on equity of 14.64% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech37.17% 14.64% 13.28% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has more volatility and risk, KRYS or ITCI? Krystal Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Which has stronger valuation & earnings, KRYS or ITCI? Krystal Biotech has higher earnings, but lower revenue than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$333.45M12.84$89.16M$4.1635.62Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Do insiders & institutionals hold more shares of KRYS or ITCI? 86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryKrystal Biotech beats Intra-Cellular Therapies on 13 of the 17 factors compared between the two stocks. Get Krystal Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRYS vs. The Competition Export to ExcelMetricKrystal BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.28B$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.07%4.01%P/E Ratio35.6220.7128.2120.26Price / Sales12.84292.31432.3899.78Price / Cash31.9542.1137.1257.67Price / Book4.507.638.045.49Net Income$89.16M-$55.05M$3.19B$250.45M7 Day Performance3.61%8.43%3.63%4.79%1 Month Performance5.59%5.42%4.06%7.68%1 Year Performance-27.06%2.03%30.02%16.44% Krystal Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRYSKrystal Biotech4.6729 of 5 stars$148.17-1.0%$213.75+44.3%-25.3%$4.28B$333.45M35.62210Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionITCIIntra-Cellular Therapies0.6588 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0949 of 5 stars$20.52+1.1%$37.60+83.2%-18.4%$13.02B$3.12B11.662,682Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.768 of 5 stars$15.08flat$16.95+12.4%-7.9%$12.59B$325.54B22.8527,811MRNAModerna4.3051 of 5 stars$29.90-1.9%$46.61+55.9%-72.6%$11.79B$3.24B-3.425,800Trending NewsRGCRegencell Bioscience0.3692 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap UpHigh Trading VolumeVTRSViatris2.903 of 5 stars$9.20-1.3%$10.40+13.0%-18.5%$10.94B$14.74B-2.9032,000QGENQIAGEN4.0453 of 5 stars$47.49-1.8%$49.40+4.0%+20.4%$10.75B$1.98B119.075,765ASNDAscendis Pharma A/S3.6012 of 5 stars$175.98+1.0%$220.67+25.4%+28.9%$10.65B$393.54M-28.021,017News CoverageAnalyst ForecastBBIOBridgeBio Pharma4.6053 of 5 stars$43.50-1.1%$58.85+35.3%+72.8%$8.35B$221.90M-12.32400Analyst UpgradeBPMCBlueprint Medicines1.2242 of 5 stars$128.40+0.0%$128.06-0.3%+9.8%$8.29B$508.82M-51.98640Positive NewsInsider Trade Related Companies and Tools Related Companies ITCI Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives RGC Alternatives VTRS Alternatives QGEN Alternatives ASND Alternatives BBIO Alternatives BPMC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRYS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
